Sun Pharma posts 16.5% rise in Q3 net profit, declares dividend of Rs 8.50/share
Sun Pharmaceutical Industries Ltd said on Tuesday that the Food and the Drug Administration (FDA) had suspended its application for an experimental dermatological drug due to the possibility of thrombosis. Further developments are awaited.